Displaying 81 - 100 of 684
Medtronic/Intersect, In the Matter of
The Federal Trade Commission required Medtronic, Inc. to divest a key subsidiary of Intersect ENT, Inc. as a condition of acquiring Intersect. Under the FTC consent decree, Instersect’s Fiagon subsidiary, which makes ear, nose, and throat navigation systems and balloon sinus dilation products, will be sold to Hemostasis, LLC. According to the complaint, without this divestiture, the acquisition would pose a threat to future competition in the United States for both ENT navigation systems and balloon sinus dilation products. On June 30, 2022, the Commission announced the final consent agreement in this matter.
FTC Takes Second Action Against JAB Consumer Partners to Protect Pet Owners from Private Equity Firm’s Rollup of Veterinary Services Clinics
JAB/SAGE Veterinary; Analysis of Agreement Containing Consent Orders To Aid Public Comment
RWJ Barnabas Health/Saint Peter's Healthcare System, In the Matter of
The Federal Trade Commission authorized an administrative complaint and a suit in federal court to block the acquisition of Saint Peter’s Healthcare System by RWJBarnabas Health, or RWJ, which is one of the largest hospital systems in New Jersey. The complaint alleges that in Middlesex County, in the central part of the state, the acquisition will harm competition for inpatient general acute care services, which are a broad range of essential medical and surgical diagnostic and treatment services that require an overnight hospital stay. The FTC’s federal court suit seeks a temporary restraining order and preliminary injunction to stop the deal and maintain the status quo while the agency pursues an administrative trial on the merits of the case. On June 14, 2022, the parties announced that they had abandoned the transaction.
HCA Healthcare/Steward Health Care System, In the Matter of
The Federal Trade Commission authorized an administrative complaint and a suit in federal court to block the proposed merger of two large healthcare systems in Utah, alleging the deal would lead to higher prices and lower quality of care in the region surrounding Salt Lake City, known as the Wasatch Front region. The deal would impact a broad range of essential medical and surgical diagnostic and treatment services that require an overnight hospital stay, known as inpatient general acute care, the FTC alleged.
The FTC’s federal court suit sought a temporary restraining order and preliminary injunction to stop the deal and to maintain the status quo while the FTC pursues an administrative trial on the merits of the case. On June 16, 2022, the parties announced that they had abandoned the transaction.
Statement of Bureau of Competition Director Holly Vedova Regarding the Decision of Utah Healthcare Competitors HCA Healthcare and Steward Health Care System to Abandon Their Proposed Merger
Remarks of Commissioner Christine S. Wilson: An Update on Merger Enforcement
FTC Acts to Restore Competitive Markets for Gasoline and Diesel in Michigan and Ohio
FTC Chair and Commissioners to Host Public Forum Examining the Impacts of Mergers and Acquisitions on June 21
FTC Acts to Protect Pet Owners from Private Equity Firm’s Anticompetitive Acquisition of Veterinary Services Clinics
Statement of Chair Lina M. Khan, Joined by Commissioner Rebecca Kelly Slaughter and Commissioner Alvaro M. Bedoya Regarding JAB Consumer Fund/SAGE Veterinary Partners
Concurring Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson
Buckeye/Magellan; Analysis of Agreement Containing Consent Orders To Aid Public Comment
FTC Sues to Block Merger Between Utah Healthcare Rivals HCA Healthcare and Steward Health Care System
FTC Acts to Protect South Carolina and Alabama Markets from Anticompetitive Gasoline Terminal Deal
FTC Sues to Block Merger Between New Jersey Healthcare Rivals RWJBarnabas Health and Saint Peter’s Healthcare System
Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson in the Matter of Buckeye Partners/Magellan Midstream Partners
FTC Acts to Protect Patients Who Rely on Medical Instruments Used in Sinus Procedures
Hikma Pharmaceuticals PLC/Custopharm, Inc.; Analysis of Agreement Containing Consent Orders To Aid Public Comment
Displaying 81 - 100 of 684